Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT01200953
First received: September 11, 2010
Last updated: April 2, 2014
Last verified: March 2014

September 11, 2010
April 2, 2014
August 2010
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01200953 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases
Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases

Background:

- Increased clinical attention has been paid to the evaluation and management of bioterrorism-related illness (such as anthrax infection) and emerging infectious diseases (such as Severe Acute Respiratory Syndrome [SARS] and new strains of influenza). However, evaluation and treatment data for these illnesses are often limited because human infections to date have been relatively limited. Further knowledge about diseases of bioterrorism concern and emerging infectious diseases may lead to more effective forms of therapy to prevent disease-related illnesses and deaths.

Objectives:

- To apply standardized, documented, and carefully monitored evaluation and treatment methods for bioterrorism- and biodefense-related illnesses and emerging infectious diseases at the National Institutes of Health Clinical Center.

Eligibility:

  • Individuals at least 2 years of age who have confirmed or suspected infection by a biodefense or bioterrorism agent, or an emerging infectious disease agent.
  • Individuals at least 2 years of age who have confirmed or suspected exposure to a biodefense or bioterrorism agent, an emerging infectious disease agent, or who have close exposure to an individual who is suspected of being infected with one of these agents.
  • Health care workers who are involved in medical treatment of the abovementioned infected or exposed individuals.

Design:

  • All eligible persons will have an initial screening evaluation to determine the circumstances of possible infectious exposure (e.g., where, when, and how exposed), current medical condition and medical care given, and any aspects of medical history that might be relevant to the exposure.
  • Participants may be seen in an outpatient clinic or in the Special Clinical Studies Unit (SCSU) at the National Institutes of Health (NIH). The NIH SCSU is a hospital ward specially designed to minimize the risk of spreading infection to others.
  • Upon admission, participants will provide blood and urine samples, have an electrocardiogram to measure heart activity, and have specific tests or procedures associated with the particular infectious agent.
  • Participants who develop illnesses will be treated with the standard of care for known diseases or with experimental measures, depending on the nature of the illness. Separate consent may be required for these treatments.
  • Participants will remain on this study for at least 1 year following the period of active evaluation and treatment. Participants may be asked to come to the NIH outpatient clinic on a periodic basis for medical evaluations and blood tests, and may be asked to keep a diary card to record any unusual signs or symptoms of possible infection.

Since the fall 2001 distribution of letters containing Bacillus anthracis spores via the US postal system, increased attention has been paid to the evaluation and management of bioterrorism-related illness. Similarly, the emergence of Severe Acute Respiratory Syndrome (SARS) and other infectious diseases, along with the ongoing threat of global influenza pandemics, have fostered intensive interest in the evaluation and management of emerging infections both in the US and internationally. Data to this end are often limited, however, in that while many such diseases exist in nature, human illness may only rarely occur. The primary purpose of this protocol is to apply standardized, documented, and carefully monitored evaluation and prophylactic and treatment measures in the event of suspected or confirmed exposure to the causative agent of any disease of bioterrorism concern (whether of natural or deliberate origin), to agents under study in biodefense-related research laboratories, or to emerging infectious disease pathogens. Other goals include the characterization of natural history and clinical course of such diseases via the evaluation of close contacts of potentially exposed persons, as well as those who have recovered from illness; the elucidation of the pathophysiology of such diseases; the characterization of immune responses to such diseases; and the evaluation of diagnostic tests for the rapid identification of the causative agents of such diseases in clinical specimens. Further knowledge about diseases of bioterrorism concern and emerging infectious diseases may lead to more effective forms of therapy and improve disease-related morbidity and mortality.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Occupational Accidents
  • Incubation Period, Infectious Disese
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
250
Not Provided
Not Provided
  • INCLUSION CRITERIA:

Confirmed Infection Inclusion Criteria:

  1. Laboratory diagnosis of infection by a select agent under study in a biodefense research facility, by an agent of bioterrorism, by a naturally-occurring pathogen in the environment, or by an emerging infectious disease agent, whether acute or recovering/convalescent.
  2. Clinically stable for transfer to the Clinical Center.
  3. The ability and understanding to provide written informed consent. In cases of 1) temporary incompetence due to severe illness, or 2) permanent incompetence due to a chronic condition, only persons with durable power of attorney (DPA), legal guardians, or surrogates may sign consent.

Suspected Infection Inclusion Criteria:

  1. One of the following:

    1. Close contact, within a timeframe consistent with the incubation period of an agent under study in a biodefense research facility, with an agent of bioterrorism, with a naturally-occurring pathogen in the environment, with an emerging infectious disease agent, or with a person identified as a confirmed or suspected case of contagious disease.

      • Close contact is defined as having cared for, having lived with, or having direct contact with respiratory secretions and/or body fluids of a patient identified as a suspected case of contagious disease.
      • Other contact of sufficient proximity and duration to incite reasonable concern that transmission of the causative agent of a contagious disease in the above categories may have occurred. This will be determined on an individual basis by the Principal Investigator (PI) or an Associate Investigator (AI) using best medical judgment.

      OR

    2. Penetration of the skin, within a timeframe consistent with the incubation period of a disease agent of concern, by any item with documented or suspected contamination by any agent in the above categories.

      OR

    3. Verified consumption, within a timeframe consistent with the incubation period of a disease agent of concern, of any liquid or solid with documented or suspected contamination by any agent in the categories above, whether accidental or deliberate.

      OR

    4. Verified presence, within a timeframe consistent with the incubation period of a disease agent of concern, in an area with documented or suspected release of any agent in the categories above, whether accidental or deliberate, or with endemic or enzootic foci of any of these agents above.

    AND

  2. Clinical findings consistent with infection with an agent in the categories above, whether acute or recovering/convalescent.

    AND

  3. Clinically stable for transfer to the Clinical Center.
  4. The ability and understanding to provide written informed consent. In cases of 1) temporary incompetence due to severe illness, or 2) permanent incompetence due to a chronic condition, only persons with durable power of attorney (DPA), legal guardians, or surrogates may sign consent.

Confirmed or Suspected Exposure Inclusion Criteria:

  1. One of the following:

    1. Close contact, within a timeframe consistent with the incubation period of a select agent under study in a biodefense research facility, with an agent of bioterrorism, with a naturally-occurring pathogen in the environment, with an emerging infectious disease agent, or with a person identified as a confirmed or suspected case of contagious disease.

      • Close contact is defined as having cared for, having lived with, or having direct contact with respiratory secretions and/or body fluids of a patient identified as a confirmed or suspected case of contagious disease.
      • Other contact of sufficient proximity and duration to incite reasonable concern that transmission of the causative agent of a contagious disease in the above categories may have occurred. This will be determined on an individual basis by the Principal Investigator (PI) or an Associate Investigator (AI) using best medical judgment.

      OR

    2. Penetration of the skin, within a timeframe consistent with the incubation period of a disease agent of concern, by any item with documented or suspected contamination by an agent within the categories above.

      OR

    3. Verified consumption, within a timeframe consistent with the incubation period of a disease agent of concern, of any liquid or solid with documented or suspected contamination by an agent within the categories above, whether accidental or deliberate.

      OR

    4. Verified presence, within a timeframe consistent with the incubation period of a disease agent of concern, in an area with documented or suspected release of an agent in the categories above, whether accidental or deliberate, or with endemic or enzootic foci of any of these agents above.

    AND

  2. The ability and understanding to provide written informed consent. In cases of 1) temporary incompetence due to severe illness, or 2) permanent incompetence due to a chronic condition, only persons with durable power of attorney (DPA), legal guardians, or surrogates may sign consent.

Health Care Worker Inclusion Criteria:

  1. Health care worker involved with, or anticipated to be involved with, the clinical care of above-defined patients. A health care worker is defined as anyone involved with patient care or having clinically significant patient contact.
  2. The ability and understanding to provide written informed consent.

EXCLUSION CRITERIA:

  1. Age less than 2 years.
  2. Unwillingness to enroll in a clinical research protocol governing admission and management of exposure to, or infection with, a biodefense select agent, an agent of bioterrorism concern, a naturally-occurring pathogen in the environment, or an agent of emerging infectious disease that is conducted at the NIH Clinical Center.
  3. Unwillingness to allow phlebotomy and/or storage of clinical specimens that may assist in current or future research endeavors designed to improve the diagnostic and treatment strategies relevant to the exposure or infection under consideration in the affected individual.
Both
2 Years and older
Yes
Contact: Richard T Davey, M.D. (301) 496-8029 rdavey@niaid.nih.gov
United States
 
NCT01200953
100197, 10-I-0197
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Principal Investigator: Richard T Davey, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health Clinical Center (CC)
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP